✦ LIBER ✦

Evaluation of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy: Is there a need for a more rational design?

✍ Scribed by Jian-Ming Xu; Angelo Paradiso; Howard L McLeod

Book ID: 116428229
Publisher: Elsevier Science
Year: 2004
Tongue: English
Weight: 134 KB
Volume: 40
Category: Article
ISSN: 0959-8049
DOI: 10.1016/j.ejca.2004.04.028

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Erlotinib (OSI-774, Tarceva™), a Selecti

Erlotinib (OSI-774, Tarceva™), a Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Chemotherapy for Advanced Non–Small-Cell Lung Cancer

✍ Mary Hightower; Chandra P. Belani; Vinay K. Jain 📂 Article 📅 2003 🏛 CIG Media Group, LP. 🌐 English ⚖ 78 KB

Tyrosine kinase inhibitors of the epider

Tyrosine kinase inhibitors of the epidermal growth factor receptor as adjuncts to systemic chemotherapy for muscle-invasive bladder cancer

✍ Lynsey A McHugh; T.R.Leyshon Griffiths; Marina Kriajevska; R.Paul Symonds; J.Kil 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 155 KB

Rational Approach to the Synthesis, Eval

Rational Approach to the Synthesis, Evaluation, and 68 Ga Labeling of a Novel 4-Anilinoquinoline Epidermal Growth Factor Receptor Inhibitor as a New Imaging Agent That Selectively Targets the Epidermal Growth Factor Receptor Tyrosine Kinase

✍ Theeraladanon, Chumpol; Takahashi, Nobukazu; Shiina, Masaaki; Hamada, Keisuke; T 📂 Article 📅 2010 🏛 Mary Ann Liebert 🌐 English ⚖ 968 KB

ZD1839, a selective epidermal growth fac

ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non–small cell lung cancer

✍ David Raben; Barbara A. Helfrich; Dan Chan; Gary Johnson; Paul A. Bunn Jr 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 107 KB

KRAS Mutation Is an Important Predictor

KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer

✍ Massarelli, E.; Varella-Garcia, M.; Tang, X.; Xavier, A. C.; Ozburn, N. C.; Liu, 📂 Article 📅 2007 🏛 American Association for Cancer Research 🌐 English ⚖ 196 KB

Preclinical rationale for a combined tre

Preclinical rationale for a combined treatment with irinotecan and the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) ZD1839 (Iressa) in irinotecan-refractory human colon cancer

📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 157 KB